We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Feedback Plc | LSE:FDBK | London | Ordinary Share | GB00BJN59X09 | ORD 50P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.50 | -2.50% | 97.50 | 95.00 | 100.00 | 100.00 | 97.50 | 100.00 | 7,000 | 11:34:19 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Electronic Computers | 1.03M | -2.92M | -0.2188 | -4.46 | 13M |
From Apr 2019 to Apr 2024
TIDMFDBK
RNS Number : 0086O
Feedback PLC
27 September 2019
Feedback plc
Statement re share price
Cambridge, 27 September 2019: Feedback plc (AIM: FDBK, "Feedback" or the "Company") notes the movement in the share price today. The Company notes the announcement earlier today by IQ-AI Ltd that Imaging Biometrics, IQ-AI's Milwaukee based subsidiary, today received notification that the FDA has cleared StoneChecker Software for marketing in the USA ("the FDA Clearance"). Stonechecker is a licensee of Feedback's TexRAD(R) software and the Directors believe that the Stonechecker Software uses TexRAD(R) . However, the Company is currently not able to evaluate what level of income, if any, will accrue as a result of the FDA Clearance. In addition, the FDA Clearance does not confer FDA clearance for TexRAD(R) and the Directors are now evaluating the implications of this as part of their ongoing strategic review.
A further announcement will be made in due course.
Hot Features
Premium
Enquiries:
Feedback plc +44 (0)1954 718072
Tom Oakley, CEO IR@fbk.com
Lindsay Melvin, CFO
Allenby Capital Limited (Nominated Adviser)
David Worlidge / Asha Chotai +44 (0)20 3328 5656
Peterhouse Capital Limited (Joint Broker)
Lucy Williams / Duncan Vasey +44 (0)20 7469 0936
Stanford Capital Partners Limited (Joint +44 20 3815 8880
Broker)
Patrick Claridge / John Howes
+44 (0)20 7457 2020
Instinctif Partners feedbackplc@instinctif.com
Rozi Morris/ Deborah Bell/ Phillip Marriage
Notes to editors
About Feedback plc
Feedback plc (AIM: FDBK) is a specialist medical imaging technology company providing innovative software and systems, through its fully-owned trading subsidiary, Feedback Medical Limited. Its products advance the work of radiologists, clinicians and medical researchers by improving workflows and giving unique insights into diseases, particularly cancer. Feedback Medical works with customers globally from headquarters in the internationally renowned scientific hub of Cambridge, UK. Its proprietary technologies are TexRAD(R) , the quantitative texture analysis tool and Cadran, a picture archiving communication system (PACS). The Company has recently announced the launch of its new messaging and image transfer product Bleepa(TM). For more information, see www.fbk.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
SPMBXGDCISDBGCR
(END) Dow Jones Newswires
September 27, 2019 09:52 ET (13:52 GMT)
1 Year Feedback Chart |
1 Month Feedback Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
